Table 1.
Characteristics | No. (%) | P value | |
---|---|---|---|
Seizure free (n = 189) | Uncontrolled (n = 125) | ||
Sex | 0.808 | ||
Male | 122 (64.4) | 79 (63.2) | |
Female | 67 (35.6) | 46 (36.8) | |
Age at last follow-up, m | 0.086 | ||
Median (IQR) | 68 (45–89) | 59 (42–85) | |
Range | 25–129 | 5–172 | |
Age at onset, m | 0.023 | ||
Median (IQR) | 5.5 (3.5–8) | 4 (2–7.5) | |
Range | 0–23.6 | 0–23 | |
Median time between onset and treatment initiation, m | 0.05 | ||
Median (IQR) | 1 (0–2.5) | 1.9 (0–3.75) | |
Range | 0–19 | 0–34 | |
Median time between onset and first-line therapy initiation, m | 0.003 | ||
Median (IQR) | 3 (1–6.45) | 4.5 (2–15) | |
Range | 0–89.5 | 0–76 | |
Etiology | 0.445 | ||
Genetic | 19 (10.1) | 20 (16) | |
Structural-congenital | 8 (4.2) | 4 (3.2) | |
Structural-acquired | 46 (24.3) | 36 (28.8) | |
Structural-genetic | 9 (4.8) | 4 (3.3) | |
Metabolic | 5 (2.6) | 1 (0.8) | |
Infectious | 1 (0.5) | 0 | |
Unknown | 101 (53.4) | 60 (48) |
%: percentage; IQR: interquartile range; m: months; No: numbers.